Tirzepatide - role in obesity, health and physical wellness. Information overview
DOI:
https://doi.org/10.12775/QS.2025.38.58191Keywords
Tirzepatide, GLP-1, GIP, GIP/GLP-1 dual agonist, Obesity, Diabetes Mellitus type 2, SURMOUNT, FDA, EMAAbstract
Nowadays there is an increasing number of people with overweight and obesity all around the world. Unhealthy food, sweets and fast foods are available everywhere, that causes self-perpetuating problem. Food restriction is an obvious treatment, but it is difficult to achieve. A certain solution are GLP-1 agonists using to treat type 2 diabetes. Last studies shown that that medicaments may be effective in promoting weight loss. Tirzepatide as a novelty and is a long-acting dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It can be very supportive in the fight against obesity.
References
Mahmood Safaei, Elankovan, Sundararajan, Maha Driss, Wadii Boulila, Azrulhizam Shapi’i, 2021, A systematic literature review on obesity: Understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity DOI: 10.1016/j.compbiomed.2021.104754
Connor B. Weir, Arif Jan., 2023, BMI Classification Percentile And Cut Off Points Bookshelf ID: NBK541070
Marie-Eve Piché, André Tchernof, Jean-Pierre Després, 2020, Obesity Phenotypes, Diabetes, and Cardiovascular Diseases DOI: 10.1161/CIRCRESAHA.120.316101
B. Conway, A. Rene, 2004, Obesity as a disease: no lightweight matter DOI: 10.1111/j.1467-789X.2004.00144.x
THE GLOBAL HEALTH OBSERVATORY; Obesity https://www.who.int/data/gho/indicator-metadata-registry/imr-details/3420
2024, World Health Organization; Obesity and overweight https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
2024, World Health Organization; One in eight people are now living with obesity https://www.who.int/news/item/01-03-2024-one-in-eight-people-are-now-living-with-obesity
World Obesity; Economic impact of overweight and obesity to surpass $4 trillion by 2035 https://www.worldobesity.org/news/economic-impact-of-overweight-and-obesity-to-surpass-4-trillion-by-2035
A Romero-Corral, V K Somers, J Sierra-Johnson, R J Thomas, M L Collazo-Clavell, J Korinek, T G Allison, J A Batsis, F H Sert-Kuniyoshi, 2008, F Lopez-Jimenez Accuracy of Body Mass Index to Diagnose Obesity In the US Adult Population DOI: 10.1038/ijo.2008.11
Piotr Jankowski, Paweł Kozieł, Andrzej Pająk, 2023 ,Body mass index and waist circumference in patients with established coronary artery disease over a 20-year period DOI: 10.5603/CJ.a2023.0001
George A. Bray, 2023, Beyond BMI DOI: 10.3390/nu15102254
Daniela Franz, Jan Syväri, Dominik Weidlich, Thomas Baum, Ernst J Rummeny, Dimitrios C Karampinos, 2018, Magnetic Resonance Imaging of Adipose Tissue in Metabolic Dysfunction DOI: 10.1055/a-0612-8006
Hongbo Dong, Hong Cheng, Jingfan Xiong, Li Liu, Yiwen Huang, Xinying Shan, Hongmin Fan, Xi Wang, Xia Wang, Pei Xiao, Fangfang Chen, Jie Mi, 2024, Body fat variation and redistribution across different stages of life measured by dual-energy x-ray absorptiometry DOI: 10.7189/jogh.14.04247
2022, PubChem CID 163285897 https://pubchem.ncbi.nlm.nih.gov/compound/163285897
2022, Tirzepatide https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=structure&ligandId=11429
Gabriela Anglart1, Laura Janik1, Katarzyna Dettlaff, 2023, Tirzepatyd – nowy analog hormonów inkretynowych https://stn.ump.edu.pl/prace_naukowe/05_SZ_Tirzepatyd_n.pdf
Thinzar Min, Stephen C. Bain, 2020, The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials DOI: 10.1007/s13300-020-00981-0
Yutaka Seino, Mitsuo Fukushima, Daisuke Yabe, 2010, GIP and GLP-1, the two incretin hormones: Similarities and differences DOI: 10.1111/j.2040-1124.2010.00022.x
Qiyuan Keith Liu, 2024, Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists DOI: 10.3389/fendo.2024.1431292
Christophe De Block MD, Clifford Bailey PhD, Carol Wysham MD, Andrea Hemmingway PhD, Sheryl Elaine Allen MD, Jennifer Peleshok PhD, 2022, Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective DOI: 10.1111/dom.14831
Michael A. Nauck & David A. D‘Alessio , 2022, Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction DOI: 10.1186/s12933-022-01604-7
SUMMARY OF PRODUCT CHARACTERISTICS https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf
Tim Heise, J. Hans DeVries, Shweta Urva, Jing Li, Edward J. Pratt, Melissa K. Thomas, Kieren J. Mather, Chrisanthi A. Karanikas, Julia Dunn, Axel Haupt, Zvonko Milicevic, Tamer Coskun, 2023, Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes DOI: 10.2337/dc22-1710
Ricardo J. Samms, Michael E. Christe, Kyla A.L. Collins, Valentina Pirro, Brian A. Droz, Adrienne K. Holland, Jessica L. Friedrich, Samantha Wojnicki, Debra L. Konkol, Richard Cosgrove, Ellen P.S. Conceição Furber, Xiaoping Ruan, Libbey S. O’Farrell, Annie M. Long, Mridula Dogra, Jill A. Willency, Yanzhu Lin, Liyun Ding, Christine C. Cheng, Over Cabrera, Daniel A. Briere, Jorge Alsina-Fernandez, Ruth E. Gimeno, Julie S. Moyers, Tamer Coskun, Matthew P. Coghlan, Kyle W. Sloop, and William C. Roell, 2021, GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice DOI: 10.1172/JCI146353
Karen Schneck, Shweta Urva, 2024, Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide https://doi.org/10.1002/psp4.13099
Khashayar Farzam, Preeti Patel., 2024, Tirzepatide https://www.ncbi.nlm.nih.gov/books/NBK585056/
Baptist Gallwitz, 2022, Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity DOI: 10.3389/fendo.2022.1004044
Rahul Mishra, Rishi Raj, Ghada Elshimy, Isain Zapata, Lakshmi Kannan, Priyanka Majety, Dinesh Edem, Ricardo Correa, 2023, Adverse Events Related to Tirzepatide DOI: 10.1210/jendso/bvad016
Michael A. Nauck & David A. D’Alessio, 2022, Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction DOI: 10.1186/s12933-022-01604-7
Ildiko Lingvay MD, Alice YY. Cheng MD, Joshua A. Levine MD, Elisa Gomez-Valderas MSc, Sheryl E. Allen MD, Kari Ranta MD, Amelia Torcello-Gómez PhD, Vivian T. Thieu PhD, 2022, Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies DOI: 10.1111/dom.14943
Carel W. le Roux, Shuyu Zhang, Louis J. Aronne, Robert F. Kushner, Ariana M. Chao, Sriram Machineni, Julia Dunn, Farai B. Chigutsa, Nadia N. Ahmad, Mathijs C. Bunck, 2022, Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program DOI: 10.1002/oby.23612
Ania M. Jastreboff, M.D., Ph.D., Louis J. Aronne, M.D., Nadia N. Ahmad, M.D., M.P.H., Sean Wharton, M.D., Pharm.D., Lisa Connery, M.D., Breno Alves, M.D., Arihiro Kiyosue, M.D., Ph.D., Shuyu Zhang, M.S., Bing Liu, Ph.D., Mathijs C. Bunck, M.D., Ph.D., and Adam Stefanski, M.D., 2022, Tirzepatide Once Weekly for the Treatment of Obesity https://www.nejm.org/doi/10.1056/NEJMoa2206038
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) https://clinicaltrials.gov/study/NCT04184622
Prof W Timothy Garvey MD, Juan P Frias, MD, Ania M Jastreboff, MD, Prof Carel W le Roux, MD, Prof Naveed Sattar, MD, Diego Aizenberg, MD, 2023, Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial DOI: 10.1016/S0140-6736(23)01200-X
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (SURMOUNT-2) https://clinicaltrials.gov/study/NCT04657003
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (SURMOUNT-3) https://clinicaltrials.gov/study/NCT04657016
Thomas A. Wadden, Ariana M. Chao, Sriram Machineni, Robert Kushner, Jamy Ard, Gitanjali Srivastava, Bruno Halpern, Shuyu Zhang, Jiaxun Chen, Mathijs C. Bunck, Nadia N. Ahmad & Tammy Forrester, 2023, Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial DOI: 10.1038/s41591-023-02597-w
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss (SURMOUNT-4) https://clinicaltrials.gov/study/NCT04660643
Louis J. Aronne, MD, Naveed Sattar, MD, Deborah B. Horn, DO, MPH, Harold E. Bays, MD, Sean Wharton, MD, Wen-Yuan Lin, MD, PhD, Nadia N. Ahmad, MD, MPH, Shuyu Zhang, MSc, Ran Liao, PhD, Mathijs C. Bunck, MD, PhD, Irina Jouravskaya, MD, PhD, Madhumita A. Murphy, MD, 2023, Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial DOI: 10.1001/jama.2023.24945
Julio Rosenstock, Luis Vázquez, Stefano Del Prato, Denise Reis Franco; Govinda Weerakkody, Biyue Dai, Laura Fernández Landó, Brandon K. Bergman, Angel Rodríguez, 2023, Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials DOI: 10.2337/dc23-0872
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Anna Hanslik, Magdalena Mendak, Agata Białek, Agnieszka Walczak, Adrian Hovagimyan, Monika Olszanecka, Tomasz Olszanecki
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 69
Number of citations: 0
